Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 20/20 | 1.00 |
| ▸ | BCL2 | P10415 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL554408 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2 | |
| SCHEMBL29414144 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2 | |
| SCHEMBL553584 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2 | |
| SCHEMBL554641 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2 | |
| SCHEMBL554407 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2 | |
| SCHEMBL554642 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2 | |
| SCHEMBL553586 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2 | |
| SCHEMBL553585 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2 | |
| SCHEMBL21081933 | 0.95 | BCL2L1 (0.91) | BCL2L1BCL2 | |
| SCHEMBL21081700 | 0.95 | BCL2L1 (0.91) | BCL2L1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601177-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2017-10-18 | — | — | EP | claimed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | claimed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | claimed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | claimed |
| US-20240115716-A1 | THERAPEUTIC DENDRIMERS | ASTRAZENECA UK LIMITED (GB) | 2024-04-11 | — | — | US | disclosed |
| US-20240016946-A1 | DRUG-LOADED MACROMOLECULE AND PREPARATION METHOD THEREFOR | SHANGHAI SHENGDI PHARMACEUTICAL CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20230250077-A1 | SULFONYLBENZAMIDE DERIVATIVE AND CONJUGATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-11717574-B2 | Therapeutic dendrimers | ASTRAZENECA AB (SE) | 2023-08-08 | — | — | US | disclosed |
| US-11717574-B2 | Therapeutic dendrimers | ASTRAZENECA AB (SE) | 2023-08-08 | — | — | US | disclosed |
| US-11717574-B2 | Therapeutic dendrimers | ASTRAZENECA AB (SE) | 2023-08-08 | — | — | US | disclosed |
| US-20220273807-A1 | CONJUGATES FOR USE IN METHODS OF TREATING CANCER | ASTRAZENECA AB (SE) | 2022-09-01 | — | — | US | disclosed |
| US-20210060172-A1 | THERAPEUTIC DENDRIMERS | ASTRAZENECA AB (SE) | 2021-03-04 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| WO-2012017251-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11717574-B2 | Therapeutic dendrimers | CD44, ITGAV, FOLR1 | BCL2L1 2257/4885BCL2 1164/4885 |
| US-20220273807-A1 | CONJUGATES FOR USE IN METHODS OF TREATING CANCER | CD44, FOLH1, SLC17A5 | BCL2L1 3275/4885BCL2 2102/4885 |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | BCL2L1 2/4885BCL2 1/4885 |
| US-20210060172-A1 | THERAPEUTIC DENDRIMERS | CD44, ITGAV, FOLR1 | BCL2L1 2257/4885BCL2 1164/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | BCL2L1 2/4885BCL2 1/4885 |
| US-20240115716-A1 | THERAPEUTIC DENDRIMERS | CD44, ITGAV, FOLR1 | BCL2L1 2257/4885BCL2 1164/4885 |
| US-20240016946-A1 | DRUG-LOADED MACROMOLECULE AND PREPARATION METHOD THEREFOR | MRPL38, MRPS27, MRPS18A | BCL2L1 2233/4885BCL2 2922/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | BCL2L1 6/4885BCL2 1/4885 |
| US-20230250077-A1 | SULFONYLBENZAMIDE DERIVATIVE AND CONJUGATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | GLP1R, HADHB, SUCNR1 | BCL2L1 1220/4885BCL2 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.